Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• What Delta’s report tells investors in American and United
• Goldman Sachs reports global fund inflows for week of July 8